Heliox for Neonate With Acute Respiratory Distress Syndrome (ARDS)
NCT ID: NCT03217149
Last Updated: 2017-07-13
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
UNKNOWN
NA
200 participants
INTERVENTIONAL
2017-09-01
2020-08-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Surfactant for Neonate With Acute Respiratory Distress Syndrome (ARDS)
NCT03217162
Transfusion of Red Blood Cells for Acute Respiratory Distress Syndrome(ARDS) in Neonates
NCT03296059
Extubation Readiness Study in Very Low Birthweight Infants
NCT01471431
NCPAP + Heliox as a Treatment for Infant Respiratory Distress Syndrome (RDS)
NCT01383850
Acute Respiratory Distress Syndrome(ARDS) in Neonates
NCT03227289
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
QUADRUPLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
heliox combined with mechanical ventilation (MV)
heliox combined with mechanical ventilation (MV) is given to infant with ARDS
heliox combined with MV
heliox combined with MV is given to infant with ARDS
mechanical ventilation
mechanical ventilation (MV) is given to infant with ARDS
MV
MV is given to infant with ARDS
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
heliox combined with MV
heliox combined with MV is given to infant with ARDS
MV
MV is given to infant with ARDS
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
2. diagnosis of ARDS
3. informed parental consent has been obtained
Exclusion Criteria
2. transferred out of the neonatal intensive care unit without treatment
30 Minutes
28 Days
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Daping Hospital and the Research Institute of Surgery of the Third Military Medical University
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Ma Juan
Principal Investigator
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Shi Yuan, PhD,MD
Role: STUDY_DIRECTOR
Daping Hospital and the Research Institute of Surgery of the Third Military Medical University
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Department of Pediatrics, Daping Hospital, Third Military Medical University
Chongqing, Chongqing Municipality, China
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
heliox for ARDS
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.